TrialLancet (London, England)2021

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.

Anthony Marson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.